Evidence map›Paper›PMID 42474392›Full record

ArticleJournal of clinical microbiology2026

Health system implementation of clinical decision support to optimize respiratory pathogen profile utilization.

Erika M Flores, Yun Li, Jenna T Reece, Mika Epps, Onyeka Nwankwo, Judith O'Donnell, Laurel Glaser, Kyle G Rodino

Abstract read
In one paragraph

Article in Journal of clinical microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Erika M FloresDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Yun LiDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Jenna T ReeceDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Mika EppsPenn Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Onyeka NwankwoPenn Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Judith O'DonnellPenn Medicine, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.
Laurel GlaserDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Kyle G RodinoDepartment of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA.ORCID 0000-0001-9308-4810

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overuse of respiratory pathogen profiles (RPPs) in immunocompetent patients offers limited clinical benefit and may contribute to unnecessary hospital costs. Evidence supports RPP use primarily in severely ill, immunosuppressed, or pediatric patients, while smaller, targeted tests are more appropriate for routine cases . The goal of this study was to evaluate the impact of a clinical decision support (CDS) intervention on RPP utilization and associated reagent costs. We reviewed RPP utilization across the health system and implemented a CDS tool with pre-approved clinical indications to guide appropriate RPP ordering or redirect testing to a smaller seasonal respiratory viral profile (SRVP). Initiation of an RPP order through the CDS tool presented the SRVP as the default, pre-selected option, with users prompted with specific built-in clinical indications before selecting whether to proceed with an RPP or SRVP. Data from inpatient and emergency department settings from January 2022 to January 2026 were used to assess RPP ordering practices pre- and post-CDS implementation. The impact of the CDS implementation on RPP orders was assessed using an interrupted time series analysis. Retrospective analysis revealed a year-to-year increase in RPP orders from 2022 to 2024. After CDS implementation, there was an immediate and significant decrease in RPPs compared to the pre-CDS period (-946.70, 95% CI: -1,320.2 to -573.2). This corresponded to $2.26 million in reagent cost savings. Overall, the introduction of the CDS successfully reduced the overutilization of large respiratory pathogen syndromic panels by encouraging the use of a SRVP when clinically appropriate. IMPORTANCE: Diagnostic stewardship ensures that multiplex molecular assays are used to deliver the right test, for the right patient, at the right time. Through coordinated input from interdisciplinary teams across the diagnostic pathway, stewardship enhances test selection, resource utilization, and interpretation of complex syndromic panels. Although multiplex PCR assays offer high sensitivity, their ability to detect residual nucleic acid from nonviable or colonizing organisms can create diagnostic ambiguity; therefore, it is important to have stewardship frameworks in place to guide appropriate test ordering, timing, and result interpretation and to avoid misinterpreting results. Through integration of laboratory expertise and evidence-based indications, diagnostic stewardship enhances the clinical value of multiplex testing and limits unnecessary treatment and downstream costs.

Indexed as

Decision Support Systems, ClinicalRespiratory Tract InfectionsHumansMolecular Diagnostic TechniquesRetrospective Studiesdiagnostic stewardshipmultiplex PCRrespiratory pathogen profileseasonal respiratory viruses

Identifiers

PMID42474392
PMCPMC13463821

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.